Cart
sales@molnova.com
Home - Products - Angiogenesis - EGFR - Matuzumab

Matuzumab

CAS No. 339186-68-4

Matuzumab( —— )

Catalog No. M22153 CAS No. 339186-68-4

Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 516 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Matuzumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
  • Description
    Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    339186-68-4
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Rob C. Roovers, et al. A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth.Int J Cancer. 2011 Oct 15; 129(8): 2013–2024.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • JBJ-04-125-02

    JBJ-04-125-02 (0-1000 nM; 72 hours; H1975 cells) treatment could inhibit cell proliferation of H1975 cells at low nanomolar concentrations.

  • Withanolide A

    Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans.

  • Lapatinib

    A reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.

Sign In Join Free